U.S. Stem Cell Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume838,426 shs
Average Volume3.03 million shs
Market Capitalization$5.20 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive USRM News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

U.S. Stem Cell logo

About U.S. Stem Cell

U.S. Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

U.S. Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

What stocks does MarketBeat like better than U.S. Stem Cell?

Wall Street analysts have given U.S. Stem Cell a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but U.S. Stem Cell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting U.S. Stem Cell?

U.S. Stem Cell saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 60,100 shares, an increase of 84.9% from the August 15th total of 32,500 shares. Based on an average trading volume of 1,156,000 shares, the short-interest ratio is currently 0.1 days.
View U.S. Stem Cell's Short Interest

When is U.S. Stem Cell's next earnings date?

U.S. Stem Cell is scheduled to release its next quarterly earnings announcement on Friday, July 15th 2022.
View our earnings forecast for U.S. Stem Cell

How were U.S. Stem Cell's earnings last quarter?

U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 EPS for the quarter. The company earned $1.30 million during the quarter.
View U.S. Stem Cell's earnings history

How has U.S. Stem Cell's stock been impacted by COVID-19?

U.S. Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, USRM shares have increased by 86.9% and is now trading at $0.0114.
View which stocks have been most impacted by COVID-19

Who are U.S. Stem Cell's key executives?

U.S. Stem Cell's management team includes the following people:
  • Miguel Tomás, President, CEO, CFO & Director

Who are some of U.S. Stem Cell's key competitors?

What other stocks do shareholders of U.S. Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM) and (BGSF).

What is U.S. Stem Cell's stock symbol?

U.S. Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How do I buy shares of U.S. Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is U.S. Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.01.

How much money does U.S. Stem Cell make?

U.S. Stem Cell has a market capitalization of $5.20 million and generates $280,000.00 in revenue each year.

How many employees does U.S. Stem Cell have?

U.S. Stem Cell employs 11 workers across the globe.

What is U.S. Stem Cell's official website?

The official website for U.S. Stem Cell is www.us-stemcell.com.

Where are U.S. Stem Cell's headquarters?

U.S. Stem Cell is headquartered at 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325.

How can I contact U.S. Stem Cell?

U.S. Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at (954) 835-1500 or via email at [email protected].

This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.